Organophosphate Poisoning: Evidence‑Based Clinical Management and Role of Cholinesterase Testing

Diagnostic Role of Cholinesterase Measurements

Red blood cell (RBC) cholinesterase activity < 50 % of normal confirms significant organophosphate exposure and provides objective evidence when the diagnosis is uncertain. 2
Cholinesterase levels confirm exposure and correlate with severity only at the initial presentation; they must never delay or guide antidotal therapy because clinical symptoms—not laboratory values—should drive treatment decisions. 1, 2

Normal or mildly reduced cholinesterase levels do not exclude clinically significant poisoning and should never be used to withhold or delay atropine, pralidoxime, or benzodiazepines. 2
The American Heart Association states that treatment urgency is based on clinical signs, not cholinesterase values; immediate atropine administration is recommended based on symptoms. 1, 3
Cholinesterase measurements cannot predict the intermediate syndrome (proximal muscle weakness 24‑96 h post‑exposure) or organophosphate‑induced delayed polyneuropathy (1‑3 weeks later). 2
Enzyme activity may remain suppressed for up to 6 weeks in untreated patients, illustrating a prolonged dissociation between laboratory values and clinical status. 3
Immediate management must proceed on the basis of clinical presentation alone; awaiting laboratory results should not postpone therapy. 1, 3

Atropine: 1–2 mg IV for adults (0.02 mg/kg for children), repeat every 5 minutes and titrate to resolution of bronchorrhea, bronchospasm, and bradycardia; typical cumulative dose 10–20 mg in the first 2–3 hours. (American Heart Association) 1, 3
Pralidoxime: 1–2 g IV loading dose for adults (25–50 mg/kg for children) followed by continuous infusion of 400–600 mg/h (10–20 mg/kg/h for children); administer early before enzyme “aging.” (American Heart Association) 1
Benzodiazepines for seizures/agitation: diazepam 0.2 mg/kg IV or midazolam 0.05–0.1 mg/kg IV. (American Heart Association) 1, 3
Early endotracheal intubation is indicated for life‑threatening poisoning; avoid succinylcholine and mivacurium. (American Heart Association) 1, 3

Pralidoxime receives a Class 2a recommendation with Level A evidence from the American Heart Association, and should be administered regardless of the availability or result of cholinesterase testing. 1

Discontinuation of atropine should be guided by clinical endpoints (clear lungs, dry skin, heart rate > 80 bpm, adequate blood pressure), not by normalization of cholinesterase levels. 1, 3
Do not delay antidotal therapy to obtain cholinesterase results; symptom‑driven treatment takes absolute priority. 1, 2

The U.S. Environmental Protection Agency concluded that neurodevelopmental effects in pregnant women and children occur at exposure levels below those causing measurable acetylcholinesterase inhibition; therefore cholinesterase measurements are not useful for assessing chronic low‑level exposure. 4, 5
Organophosphate exposure—whether acute high‑dose or chronic low‑level—can lead to persistent neurobehavioral disturbances (cognitive deficits, memory impairment, attention problems, mood disorders) lasting months to years. 2
Neurotoxicity involves mechanisms independent of cholinesterase inhibition, including neuroinflammation, protein‑kinase C signaling, insulin resistance, and disruption of dopaminergic and glutamatergic neurotransmission. 4, 5